|1.||Zhang, John H: 9 articles (01/2016 - 07/2006)|
|2.||Tang, Jiping: 9 articles (01/2016 - 04/2008)|
|3.||Deitch, Edwin A: 8 articles (11/2014 - 11/2004)|
|4.||Sharma, H S: 8 articles (01/2010 - 01/2000)|
|5.||Sharma, Aruna: 7 articles (10/2015 - 12/2007)|
|6.||Sharma, Hari Shanker: 7 articles (06/2010 - 08/2005)|
|7.||Sharma, Hari S: 6 articles (10/2015 - 01/2006)|
|8.||Maeda, Hiroshi: 5 articles (11/2015 - 01/2003)|
|9.||Patnaik, Ranjana: 5 articles (10/2015 - 08/2009)|
|10.||Lu, Qi: 5 articles (01/2011 - 11/2004)|
|1.||Brain Edema (Cerebral Edema)
01/01/1993 - "The drug was also effective in reducing the BBB breakdown by more than four fold, as compared with control (548 +/- 94 versus 128 +/- 19 ng Evans blue/g tissue; p < 0.05) and attenuating cerebral edema. "
10/01/1984 - "Clearance of ytterbium-169-labeled diethylenetriaminepentaacetic acid (169Yb-DTPA), Evans blue dye, and ventricular cerebrospinal fluid protein was measured at the two ICP levels over consecutive periods of 4 hours to confirm clearance of brain edema. "
05/01/1989 - "Brain edema was evaluated by measurement of specific gravity and planimetry study of the spread of Evans blue dye. "
01/01/2016 - "Evans blue dye extravasation (BBB permeability) was quantified 24 h post-nHI, and brain edema at 48 h. "
07/23/2015 - "TM significantly decreased brain water content and Evans Blue content, alleviated brain edema and neurological deficits after SAH. "
03/01/2015 - "Our results indicate that following ischemia-reperfusion the BBB permeability is increased in ovariectomized rats (Evans Blue extravasation) compared to the control group in the cortex, thalamus, hippocampus, cerebellum and brain stem, while in the midbrain no significant increase was detected. "
01/01/2013 - "In addition, P188 inhibited ischemia/reperfusion-induced activation of matrix metalloproteinase (MMP)-9 and leakage of Evans blue. "
12/01/2011 - "Evans blue test revealed that the vascular permeability gradually increased, and peaked at day 1 after ischemia [(6.219 ± 0.887) µg/g, P < 0.01]. "
06/01/2011 - "In both ischemia models, we observed significant differences in Evans blue (vascular permeability) and LDH (tissue injury) concentrations during the reperfusion period compared with the control group. "
06/01/2011 - "We verified a bimodal increase in the permeability of the BBB following focal ischemia by Evans blue assay. "
01/01/1980 - "The method of relative microcirculation measurement using Evan's Blue was further improved and results on applying this method to tumors treated with the Cancer Multistep Therapy (CMT) are reported. "
11/01/1999 - "Vascular permeability was evaluated with Evans Blue, and pharmacokinetic studies in MAC15A and MAC26 used high-performance liquid chromatography to monitor both PK1 uptake and dox release in the tumors. "
11/10/2015 - "Experiments with Evans blue revealed increased EPR effect in all parts of the tumor. "
01/01/2015 - "The amount of Evans Blue accumulated in the tumor of Evans Blue+iRGD group was 2.5 times that of Evans Blue group. "
05/28/2014 - "Combo NP-treated tumors became 2.75 folds more permeable than those treated with Combo Free as measured by Evans Blue. "
12/01/2005 - "Lung injury was assessed by bronchoalveolar lavage, histological study, and determination of the lung Evans Blue dye content, an index of microvascular permeability. "
05/01/2015 - "Lung injury was monitored by measurements of bronchoalveolar lavage protein content, cell count, and Evans blue extravasation and live imaging of vascular leak over 6 days using a fluorescent tracer. "
11/01/2014 - "Lung injury (permeability to Evans blue dye), polymorphonuclear leukocyte (PMN) priming (respiratory burst activity), and red blood cell (RBC) rigidity were measured. "
01/01/2013 - "Lung injury was monitored by measurements of bronchoalveolar lavage protein content, cell count and Evans blue extravasation. "
03/01/2012 - "Lung injury was assessed by measuring lung function, cytokine expression in bronchoalveolar lavage fluid, leukocyte infiltration, and microvascular permeability via Evans blue dye. "
|5.||Muscular Dystrophies (Muscular Dystrophy)
04/01/2010 - "Evans blue dye (EBD) is used to mark damaged and permeable muscle fibers in mouse models of muscular dystrophy and as an endpoint in therapeutic trials. "
01/01/2002 - "Evans Blue Dye (EBD) is widely used to study cellular membrane permeability and has recently been utilised in mdx mice to identify permeable skeletal myofibres that have become damaged as a result of muscular dystrophy. "
10/20/1997 - "We furthermore assessed Evans blue incorporation in skeletal muscle of the dystrophia muscularis (dy/dy) mouse and its milder allelic variant, the dy2J/dy2J mouse, animal models for congenital muscular dystrophy. "
10/15/2012 - "Dag1(Y890F/Y890F)/mdx mice showed a significant improvement in several parameters of muscle pathophysiology associated with muscular dystrophy, including a reduction in centrally nucleated fibres, less Evans blue dye infiltration and lower serum creatine kinase levels. "
10/01/2003 - "Furthermore, we show that systemic treatment with the proteasomal inhibitor 1) reduces muscle membrane damage, as revealed by vital staining (with Evans blue dye) of the diaphragm and gastrocnemius muscle isolated from treated mdx mice, and 2) ameliorates the histopathological signs of muscular dystrophy, as judged by hematoxylin and eosin staining of muscle biopsies taken from treated mdx mice. "
|2.||salicylhydroxamic acid (SHAM)
|3.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Immunoglobulin G (IgG)
|7.||Interleukin-6 (Interleukin 6)
|9.||Caspase 3 (Caspase-3)
|10.||Creatine Kinase (Creatine Phosphokinase)